Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Inactive · Last trade price
on Feb 16, 2024
Company Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.
Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine.
The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.
Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.
Icosavax, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Adam K. Simpson |
Contact Details
Address: 1930 Boren Ave., Suite 1000 Seattle, Washington 98101 | |
| Phone | (206) 737-0085 |
| Website | icosavax.com |
Stock Details
| Ticker Symbol | ICVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001786255 |
| CUSIP Number | 45114M109 |
| ISIN Number | US45114M1099 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam K. Simpson | President, Chief Executive Officer, Co-Founder and Director |
| Niranjan Kanesa-thasan M.D. | Chief Medical Officer |
| Dr. Cassia Cearley Ph.D. | Treasurer and Chief Business Officer |
| Neil King Ph.D. | Chair of Scientific Advisory Board and Co-Founder |
| Dr. David Baker M.D., Ph.D. | Co-founder and Member of Scientific Advisory Board |
| Thomas Joseph Russo C.F.A. | Chief Financial Officer |
| Jennifer Raymond | Senior Vice President of Technical Operations |
| Elizabeth Bekiroglu | General Counsel and Corporate Secretary |
| Lori Stewart | Senior Vice President of People and Culture |
| Dr. Ami Shah Brown MPH, Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2024 | SC TO-T/A | Filing |
| Feb 20, 2024 | EFFECT | Notice of Effectiveness |
| Feb 20, 2024 | 25-NSE | Filing |
| Feb 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 20, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 20, 2024 | SC 14D9/A | Filing |
| Feb 20, 2024 | SC TO-T/A | Filing |
| Feb 15, 2024 | SC TO-T/A | Filing |
| Feb 15, 2024 | SC 14D9/A | Filing |